Vimarsana
Biggest News Aggregation in the World

Page 2 - Anthony Woolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anthony Woolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anthony Woolf Today - Breaking & Trending Today

Over 840 Million People Worldwide Will Suffer Back Pain By 2050: Study - Vimarsana News

Over 840 Million People Worldwide Will Suffer Back Pain By 2050: Study

The continued lack of a consistent approach to back pain treatment, and limited treatment options have researchers concerned that this will lead to a healthcare crisis, as low back pain is the leading cause of disability in the world, they said.

Source: india.com
In 2050, over 800 million people globally est - Vimarsana News

In 2050, over 800 million people globally est

Study estimates there will be over 800 million cases of low back pain in 2050, a 36 percent increase from 2020. With an ageing population, researchers say we must ‘put the brakes’ on low back pain cases before the burden becomes too great for our healthcare system.

84 Crore People Globally May Suffer Back Pain By 2050: Lancet study - Vimarsana News

84 Crore People Globally May Suffer Back Pain By 2050: Lancet study

More than 840 million people worldwide will suffer back pain by 2050, largely due to population increase and the ageing people, according to a modelling study published in the Lancet Rheumatology journal.

Over 800 million people globally may suffer back pain by 2050: Lancet study - Vimarsana News

Over 800 million people globally may suffer back pain by 2050: Lancet study

More than 840 million people worldwide will suffer back pain by 2050, largely due to population increase and the ageing people, according to a modelling study published in the Lancet Rheumatology journal.

Over 800 million people may suffer back pain by 2050: Lancet study - Vimarsana News

Over 800 million people may suffer back pain by 2050: Lancet study